Key Points
- Elena Ridloff, a Kymera Therapeutics director, sold 7,400 shares on March 31 at an average price of $85.37 for about $631,738 and sold another 4,600 shares on April 1 at $85.42 (~$392,932).
- KYMR trades near $85.40 (52‑week range $19.44–$103.00) with a $6.97B market cap; the company recently missed quarterly estimates (EPS -$0.97 vs -$0.77 est., revenue $2.87M vs $14.8M) but analysts maintain a consensus "Moderate Buy" and an average price target of $118.90.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $85.42, for a total value of $392,932.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Elena Ridloff also recently made the following trade(s):
- On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The stock was sold at an average price of $85.37, for a total transaction of $631,738.00.
Kymera Therapeutics Stock Performance
Shares of NASDAQ KYMR opened at $85.40 on Friday. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The stock has a 50 day moving average price of $81.26 and a 200 day moving average price of $71.73. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of -23.21 and a beta of 2.28.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. During the same quarter in the prior year, the business posted ($0.88) EPS. The business's quarterly revenue was down 60.8% on a year-over-year basis. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the stock. Mizuho lifted their price objective on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, December 11th. Oppenheimer upped their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the company an "outperform" rating in a research report on Tuesday, December 9th. B. Riley Financial upped their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Leerink Partners raised their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an "outperform" rating in a research note on Monday, December 8th. Finally, UBS Group lifted their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.90.
Get Our Latest Stock Report on Kymera Therapeutics
Hedge Funds Weigh In On Kymera Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP raised its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC boosted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after purchasing an additional 1,124,747 shares during the period. Vanguard Group Inc. boosted its position in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after buying an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, BVF Inc. IL grew its holdings in shares of Kymera Therapeutics by 6.6% in the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company's stock valued at $240,138,000 after purchasing an additional 340,909 shares in the last quarter.
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
